dipyridamole has been researched along with Osteonecrosis in 1 studies
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.
Osteonecrosis: Death of a bone or part of a bone, either atraumatic or posttraumatic.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jin, W | 1 |
| Yang, X | 1 |
| Lu, M | 1 |
1 other study available for dipyridamole and Osteonecrosis
| Article | Year |
|---|---|
Juvenile-onset multifocal osteonecrosis in systemic lupus erythematosus: A case report.
Topics: Adolescent; Bone Density Conservation Agents; Calcitriol; Cyclophosphamide; Dipyridamole; Female; Hu | 2021 |